What is the current valuation of the US Immune Checkpoint Inhibitors Market?

As of 2024, the market valuation was 11.23 USD Billion. Read More

What is the projected market size for the US Immune Checkpoint Inhibitors Market by 2035?

The market is projected to reach 22.12 USD Billion by 2035. Read More

What is the expected CAGR for the US Immune Checkpoint Inhibitors Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 6.35%. Read More

Which applications dominate the US Immune Checkpoint Inhibitors Market?

Oncology leads the market with a valuation of 6.73 USD Billion, projected to grow to 13.46 USD Billion. Read More

What are the key mechanisms of action in the US Immune Checkpoint Inhibitors Market?

PD-1 Inhibitors are significant, with a past valuation of 4.0 USD Billion, expected to reach 8.0 USD Billion. Read More

How does the route of administration impact the market dynamics?

Intravenous administration accounted for 4.49 USD Billion, projected to grow to 8.83 USD Billion. Read More

What demographic factors influence the US Immune Checkpoint Inhibitors Market?

Comorbidities are notable, with a past valuation of 2.67 USD Billion, expected to rise to 5.34 USD Billion. Read More

Which treatment settings are most prevalent in the US Immune Checkpoint Inhibitors Market?

Hospitals represented a valuation of 3.0 USD Billion, projected to grow to 6.0 USD Billion. Read More

Who are the leading companies in the US Immune Checkpoint Inhibitors Market?

Key players include Bristol-Myers Squibb, Merck & Co., and Roche, among others. Read More

What is the growth potential for autoimmune disorders within the market?

The autoimmune disorders segment was valued at 2.25 USD Billion, expected to reach 4.5 USD Billion. Read More

US Immune Checkpoint Inhibitors Market

ID: MRFR/HC/14661-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Immune Checkpoint Inhibitors Market Research Report Information By Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor), By Application (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin lymphoma, and Others) –Market Forecast Till 2035

US Immune Checkpoint Inhibitors Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Autoimmune Disorders
  3. 4.1.3 Infectious Diseases
  4. 4.1.4 Transplant Rejection
  5. 4.1.5 Other Applications
2. 4.2 Healthcare, BY Mechanism of Action (USD Billion)
  1. 4.2.1 CTLA-4 Inhibitors
  2. 4.2.2 PD-1 Inhibitors
  3. 4.2.3 PD-L1 Inhibitors
  4. 4.2.4 Combination Therapies
  5. 4.2.5 Other Mechanisms
3. 4.3 Healthcare, BY Route of Administration (USD Billion)
  1. 4.3.1 Intravenous
  2. 4.3.2 Subcutaneous
  3. 4.3.3 Oral
  4. 4.3.4 Intramuscular
  5. 4.3.5 Other Routes
4. 4.4 Healthcare, BY Patient Demographics (USD Billion)
  1. 4.4.1 Age Groups
  2. 4.4.2 Gender
  3. 4.4.3 Ethnicity
  4. 4.4.4 Comorbidities
  5. 4.4.5 Socioeconomic Status
5. 4.5 Healthcare, BY Treatment Setting (USD Billion)
  1. 4.5.1 Hospital
  2. 4.5.2 Outpatient Clinic
  3. 4.5.3 Home Care
  4. 4.5.4 Research Institutions
  5. 4.5.5 Other Settings
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co. (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Eli Lilly and Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Regeneron Pharmaceuticals (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Amgen (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY APPLICATION
3. 6.3 US MARKET ANALYSIS BY MECHANISM OF ACTION
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6. 6.6 US MARKET ANALYSIS BY TREATMENT SETTING
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY MECHANISM OF ACTION, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY MECHANISM OF ACTION, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY TREATMENT SETTING, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY TREATMENT SETTING, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY MECHANISM OF ACTION, 2026-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
  5. 7.2.5 BY TREATMENT SETTING, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

Oncology
Autoimmune Disorders
Infectious Diseases
Transplant Rejection
Other Applications

Healthcare By Mechanism of Action (USD Billion, 2026-2035)

CTLA-4 Inhibitors
PD-1 Inhibitors
PD-L1 Inhibitors
Combination Therapies
Other Mechanisms

Healthcare By Route of Administration (USD Billion, 2026-2035)

Intravenous
Subcutaneous
Oral
Intramuscular
Other Routes

Healthcare By Patient Demographics (USD Billion, 2026-2035)

Age Groups
Gender
Ethnicity
Comorbidities
Socioeconomic Status

Healthcare By Treatment Setting (USD Billion, 2026-2035)

Hospital
Outpatient Clinic
Home Care
Research Institutions
Other Settings

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”